Regulatory filings and commercialization, potential safety and regulatory issues that could deploy the spend or terminate clinical studies. Regulatory approvals for sales, uncertain timelines, costs, and results of clinical trials and development of new products; our ability to plan, and manage cost reduction or operational efficiency initiatives; the scope and validity of intellectual property rights applicable to products being developed. Our ability to maintain our remedial actions over previously reported material weaknesses and internal controls over financial reporting and our estimates for the relative fair values on the recent agreements with Phillips. May change and change our final reporting financial results.
These and other risks are described in greater detail under the heading Risk Factors contained in our periodic SEC filings, including our annual reports on Form 10-K filed with the SEC on March 16, 2011. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this call. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future even if new information becomes available.
With that, it’s now my pleasure to turn the call over to Hansen Medical’s President and CEO, Bruce Barclay. Good afternoon, Bruce.
Bruce BarclayThank you, Matt. Good afternoon everyone. Thank you all for joining us for our first quarter 2011 conference call. We continue to make excellent progress at Hansen Medical in implementing our strategic initiatives. Growing our EP business and developing and eventually commercializing our vascular robotic system. As we noticed in this afternoon’s press release, the first quarter of 2011 was a solid start to a year that promises to be very important to us as we created a strong position for us to deliver to continue to deliver on our previously stated goals. I will go over some of the highlights of the quarter and then outline some of the expectations we have for the year before I turn the call over to Peter for a detailed look at our financial results.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV